{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-396690","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2026-09-21T20:20:00+00:00","discovered_at":"2026-09-21T20:21:00.233819+00:00","generated_at":"2026-09-21T20:21:18.184353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AnaptysBio reports FY2026 net income $176.4M; Jemperli sales up 34% YoY","bullets":["Jemperli global net sales $644M (£480M) for six months ended Jun 30, 2026, +34% YoY; Q2 $331M, +26% YoY.","FDA PDUFA Feb 2027 for Jemperli in dMMR/MSI-H rectal cancer; AZUR-1 interim results met primary cCR12 endpoint.","GSK/Tesaro litigation: trial held Jul 14-17; post-trial hearing Oct 20; judgement expected Q4 2026/Q1 2027, seeking Jemperli reversion.","Cash $164.1M at Jun 30, 2026 vs $211.6M at Dec 31, 2025; collaboration revenue $53.0M for six months.","Net income from continuing ops $176.4M ($6.09 diluted EPS) for six months; $181.5M tax benefit from valuation allowance release."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-396690","json":"https://secwatch.observer/filing/0001193125-26-396690.json","markdown":"https://secwatch.observer/filing/0001193125-26-396690.md","text":"https://secwatch.observer/filing/0001193125-26-396690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/0001193125-26-396690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000119312526396690/anab-20260921.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-21T20:21:18.184353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}